問卷

TPIDB > Principal Investigator

Principal Investigator


E-DA Hospital (在職)

Division of Thoracic Medicine

Division of Thoracic Surgery

Division of Thoracic Medicine

Division of General Internal Medicine

E-DA Hospital (在職)

更新時間:2023-09-19

邱建通
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

62Cases

2025-04-01 - 2032-12-31

Not yet recruiting
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02
  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung

  • Test Drug

    Capsules Intravenous infusion Intravenous infusion

Participate Sites
18Sites

Recruiting18Sites

2023-07-01 - 2027-11-30

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting1Sites

Recruiting8Sites

2024-01-01 - 2040-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2024-06-20 - 2027-09-01

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2017-05-01 - 2020-07-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Recruiting2Sites

Terminated8Sites

2018-12-30 - 2024-12-31

Phase I

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting4Sites

Terminated2Sites

2020-01-06 - 2026-09-05

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
14Sites

Recruiting14Sites

2020-05-01 - 2024-04-15

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting9Sites

Terminated1Sites

2020-09-15 - 2025-10-08

Phase II

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting6Sites

Terminated1Sites

2022-05-10 - 2026-06-30

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites